daglα

DO34 是一个具有选择性和高效性的二酰基甘油脂肪酶 ( DAGL-α β) 抑制剂，可损害小鼠的恐惧消退，可用于研究脂多糖炎症性疼痛。

DAGLβ-IN-1，一种针对二酰基甘油脂肪酶 β (DAGLβ) 的抑制剂，可用作DAGL特异性活性探针的通用中间体。

DO34 analog 是二酰基甘油脂肪酶 α (DAGLα) 的抑制剂，DO34 analog 也是 DO34 的一个类似物。

RHC 80267 (U-57908) 是一种选择性二酰基甘油脂酶(DAGL)抑制剂，对犬血小板的IC50为 4 μM。它抑制COX 活性和磷脂酰胆碱的水解，还抑制胆碱酯酶活性，IC50为 4 μM，增强乙酰胆碱引起的松弛。

Midaglizole hydrochloride ((±)-DG5128) (DG5128) 是有效的 α2-肾上腺素受体拮抗剂。Midaglizole hydrochloride (DG5128) 对 α2-肾上腺素能受体的亲和力 (pKi= 6.28) 比 α1-肾上腺素能受体高 7.4 倍。

(Rac)-Daglutril (SLV 306 acetic acid) 是 Daglutril 的消旋体。Daglutril 是一种口服活性的混合中性内肽酶 内皮素转化酶抑制剂，正在开发用于治疗原发性高血压和充血性心力衰竭。

Midaglizole ((±)-DG5128 free base, DG5128 free base) 是一种有效的α2-adrenoceptor 拮抗剂。Midaglizole 是一种降血糖药。Midaglizole 在具有升高血压并降低血糖水平的作用。

Vildagliptin (LAF237) 是一种选择性二肽基肽酶IV (DPP-IV) 抑制剂，在人 Caco-2 细胞中抑制 DPP-IV 的IC50为 3.5 nM。它具有出色的口服生物利用度和降血糖活性。

Daglutril, a NEP ECE inhibitor, is potentially used for the treatment of hypertension, heart failure andpulmonary. Daglutril inhibits systemic conversion of big endothelin-1 in humans.

Edaglitazone (R-483) 是一种具有口服活性、选择性和高效性的 PPARγ 激动剂，对 PPARα 和 PPARγ均显示出亲和力。Edaglitazone 显示出抗血小板活性，可用于研究糖尿病和肥胖症。

Vildagliptin carboxylic acid metabolite is the major metabolite of the dipeptidyl peptidase 4 (DPP-4) inhibitor vildagliptin in humans. Vildagliptin carboxylic acid metabolite has an IC50 value of 477 μM for DPP-4 in human Caco-2 cells. It is formed from hydrolysis of the cyano group on vildagliptin.

PNU-EDA-Gly5 is a DNA topoisomerase I inhibitor-based oligo-glycine linker-payload used for the synthesis of antibody-drug conjugates (ADCs). It consists of the DNA topoisomerase I inhibitor PNU-159682 and the linker EDA-Gly5.

Vildagliptin dihydrate (LAF237 dihydrate) is a powerful and stable dipeptidyl peptidase IV (DPP-IV) inhibitor, demonstrating selectivity with an IC50 of 3.5 nM in human Caco-2 cells. This compound exhibits exceptional oral bioavailability and significant antihyperglycemic activity [1].

Vildagliptin-d7 是 Vildagliptin 的氘代化合物。Vildagliptin 的 CAS 号为 274901-16-5。Vildagliptin 是一种选择性二肽基肽酶IV (DPP-IV) 抑制剂，在人 Caco-2 细胞中抑制 DPP-IV 的IC50为 3.5 nM。它具有出色的口服生物利用度和降血糖活性。

3',4',7-Trihydroxyflavone 是分离自蚕豆荚的黄酮苷元化合物。

Taikuguasin D aglycon 是一种天然产物，可用于生命科学领域的相关研究。其产品编号为 TN6311，CAS号为 2185847-09-8。

DH376 inhibits DAGLα in a time and dose dependent manner in mouse brain. DH376 shows picomolar activity.

In humans, two forms of diacylglycerol lipase, DAGLα and DAGLβ, generate the endocannabinoid 2-arachidonoyl glycerol by attacking DAG at the sn-1 position. O-7460 is a selective inhibitor of 2-AG biosynthesis via DAGLα (IC50 = 690 nM). It demonstrates much weaker inhibition towards human monoacylglycerol lipase and rat brain fatty acid amide hydrolase (IC50s > 10 μM) and does not bind to CB1 or CB2 cannabinoid receptors (Kis > 10 μM). At 0-12 mg kg, i.p. in mice, O-7460 was reported to dose-dependently inhibit high-fat diet intake and reduce body weight.

(R)-KT109 is the (R) isomer of the diacylglycerol lipase β (DAGLβ) inhibitor KT109 . (R)-KT109 is an inhibitor of DAGLβ (IC50 = 0.79 nM) and of DAGLα-mediated hydrolysis of 1-stearoyl-2-arachidonoyl-sn-glycerol . It also inhibits α β-hydrolase domain-containing protein 6 (ABHD6) with an IC50 value of 2.51 nM. (R)-KT109 is more potent at DAGLβ, DAGLα, and ABHD6 than (S)-KT109 .

(S)-KT109 is the (S) isomer of the diacylglycerol lipase β (DAGLβ) inhibitor KT109 . (S)-KT109 is a less potent inhibitor of DAGLβ (IC50 = 39.81 nM), DAGLα-mediated hydrolysis of 1-stearoyl-2-arachidonoyl-sn-glycerol (IC50 = 794.3 nM), and α β-hydrolase domain-containing protein 6 (ABHD6; IC50 = 630.9 nM) than (R)-KT109 .

Orlistat-d3 is intended for use as an internal standard for the quantification of orlistat by GC- or LC-MS. Orlistat is a digestive lipase inhibitor. It inhibits diacylglycerol lipase α (DAGLα), DAGLβ, α β-hydrolase domain-containing protein 12 (ABHD12), ABHD16A, and platelet-activating factor acetylhydrolase (PAF-AH; IC50s = 0.06, 0.1, 0.08, 0.03, and 0.05 µM, respectively), as well as pancreatic lipase and hormone-sensitive lipase (IC50s = 0.65 and 2.1 µg ml, respectively) but does not inhibit fatty acid amide hydrolase (FAAH) or KIAA1363 (IC50s = >100 µM for both). Orlistat decreases ionomycin-induced production of the endocannabinoid 2-arachidonoyl glycerol (2-AG) in N18TG2 murine neuroblastoma cells when used at a concentration of 1 µM. It also inhibits fatty acid synthase (FASN; Kiapp = ~0.1 µM for the human enzyme) and the proliferation of PC3 prostate cancer cells in a concentration-dependent manner. Orlistat (10 mg kg) decreases serum cholesterol levels and total bod......